ANDA 210830, held by Amneal. Ethinyl Estradiol; Etonogestrel.
As of Nov 16, 2026, ANDA 210830 (Eluryng), held by Amneal, was first approved by FDA on Dec 11, 2019, with 2 approved supplements and 0 published complete response letters.
FOR VAGINAL USE ONLY EluRyng is indicated for use by females of reproductive age to prevent pregnancy. EluRyng is an estrogen/progestin combination hormonal contraceptive (CHC) indicated for use by women to prevent pregnancy.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Dec 11, 2019 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Eluryng0.015MG/24HR;0.12MG/24HR · ring;vaginal | Ethinyl Estradiol; Etonogestrel | Rx |
| Jan 8, 2025 | Supplement 20Labeling · Standard review | Approved | None posted |
| Sep 19, 2023 | Supplement 12Labeling · Standard review | Approved | None posted |
| Dec 11, 2019 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters